An Association between Matrix Metalloproteinase-2 and TIMP-2 +853G/A Gene Polymorphisms and Multiple Sclerosis

Česká verzia

Authors: Y. Benešová ¹; A. Vašků ²; P. Štouračihash2 ^{1,3 1,3}
Authors place of work: Neurologická klinika LF MU a FN Brno ¹; Ústav patologické fyziologie, LF MU, Brno ²; CEITEC – Středoevropský technologický institut, MU, Brno ³
Published in the journal: Cesk Slov Neurol N 2012; 75/108(3): 314-319
Category: Original Paper

Summary

Background:
Matrix metalloproteinases (MMPs) play an important role in the immunopathogenesis of multiple sclerosis (MS). They are notable contributors to the progression of inflammatory process, blood-brain barrier disruption, formation of MS lesions and demyelination. The matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-2 (MMP-2) are the most important. They are expressed by T-lymphocytes and monocytes, the predominant group of inflammatory cells in active demyelinating plaques. In our previous study, we demonstrated a borderline association of MMP-2-1575G/A gene polymorphism with MS susceptibility. To date, no other genetic association study involving MMP-2 and (tissue inhibitor of metalloproteinases-2 (TIMP-2) genes variability and MS have been carried out.

Objective:
The aim of this study was to investigate the possible association of MMP-2 (–168G/T, –735C/T) and TIMP-2 (+853G/A) gene polymorphisms with MS susceptibility; to find potential gender differences; and to investigate whether these polymorphisms influence disability.

Materials and methods:
A study group consisted of 240 patients fulfilling McDonald’s criteria of MS, a control group consisted of 135 healthy volunteers. Clinical status was evaluated with the Expanded Disability Status Scale (EDSS) and the disease severity was calculated using the MS Severity Score (MSSS). Polymerase chain reaction (PCR) methods and restriction analysis were used for genotyping in MMPs genes.

Results:
We demonstrated a borderline association between TIMP-2 +853G/A gene polymorphism and a risk of developing relapsing-remitting MS (Pg = 0.04), odds ratio (OR), 1.46; 95% confidence interval (CI): 0.91–2.36). Other polymorphisms were associated neither with MS susceptibility nor with the disease phenotype. No association with disability was found.

Conclusion:
MMP-2 and TIMP-2 gene polymorphisms are not a risk factor for MS susceptibility in the Czech population.

Key words:
gene polymorphism – matrix metalloproteinases – multiple sclerosis

Zdroje

1. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251 (Suppl 5): v12–v29.

2. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52(1): 61–76.

3. Martin R, Bielekova B, Gran B, McFarland HF. Lessons from studies of antigenspecific T cell responses in multiple sclerosis. J Neural Transm Suppl 2000; 60: 361–373.

4. Hafler DA. Multiple sclerosis. J Clin Incest 2004; 113(6): 788–794.

5. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201(3): 223–226.

6. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as a major inflammatory mediators in multiple sclerosis. Brain 2003; 126(12): 2738–2749.

7. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, Brito RB, Bartoš SP, Line SP. Analysis of the MMP-9 (C-1562T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis. J Clin Periodontol 2005; 32(2): 207–211.

8. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4(2): 197–250.

9. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6(12): 931–944.

10. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192(3): 1175–1181.

11. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121(12): 2327–2334.

12. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26(4): 299–307.

13. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121(1): 159–166.

14. Galboiz Y, Shapiro S, Lahat N, Rawashden R, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 2001; 50(4): 443–451.

15. Lindberg RL, De Groot CJ, Montagne L, Freitag P, Valk P, Kappos L et al. The expression profile of matrix metalloproteinases (MMPs) and thein inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001; 124(9): 1743–1753.

16. Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 2005; 163(1–2): 157–164.

17. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26(4): 299–307.

18. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002; 1(1–2): 21–27.

19. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33(11): 2711–2717.

20. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Incest 1990; 86(5): 1496–1502.

21. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154(9): 4379–4389.

22. Montgomery AM, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1993; 1176(3): 265–268.

23. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55(3): 300–309.

24. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136(1–2): 46–53.

25. Benesová Y, Vasku A, Novotná H, Litzman J, Stourač P, Beránek M et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 2009; 15(3): 316–322.

26. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23(5): 406–415.

27. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 2006; 111(4): 289–299.

28. Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Tola MR et al. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler 2009; 15(5): 547–554.

29. Borden P, Keller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997; 7(1–2): 159–178.

30. Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H et al. Interferon-beta-1b decreased matrixmetalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 2003; 250(10): 1224–1228.

31. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 1990; 29(24): 5783–5789.

32. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003; 347(3): 739–745

33. Benesová Y, Vasků A, Stourač P, Hladíková M, Beránek M, Kadanka Z et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol 2008; 205(1–2): 105–109.

34. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58(6): 840–846.

35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33(11): 1444–1452.

36. Roxburgh RH, Seman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64(7): 1144–1151.

37. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele specific transcriptional regulation. J Biol Chem 2001; 276(10): 7549–7558.

38. Vasků A, Goldbergová M, Izakovicová Hollá L, Sisková L, Groch L, Beránek M et al. A haplotype constituted of four MMP-2 promoter polymorphisms (–1575G/A, –1306C/T, –790 T/G and –735C/T) is associated with coronary triple-vessel disease. Matrix Biol 2004; 22(7): 585–591.

39. Xu E, Xia X, Lü B, Xing X, Huang Q, Ma Y et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog 2007; 46(11): 924–929.

40. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64(20): 7622–7628.

41. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Tong S et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005; 26(6): 1117–1121.

42. Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007; 56(2): 273–280.

43. Nemec P, Goldbergová M, Svobodnik T, Polásková D, Soucek M, Vasků A. Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis. Vnitr Lek 2006; 52(4): 348–354.

44. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18(5): 748–752.

45. Wang X, Tromp G, Cole CW, Verloes A, Sakalihasan N, Yoon S et al. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and (TIMP2) in patients with aneurysms. Matrix Biol 1999; 18(2): 121–124.

46. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell and macrophage mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001; 124(11): 2203–2214.

47. Ebers G. Genetic factors in multiple sclerosis. MS Forum; Modern Management Workshop Boston 1995.

48. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PloS One 2007; 2(7): e664.

49. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39(9): 1083–1091.